Conditions: Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma
Keywords: CLL SLL
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 34
Healthy volunteers: no

Brief summary:
The purpose of this research is to evaluate a new combination of chemotherapy drugs for CLL/SLL using the drugs bendamustine (an intravenous chemotherapy drug), rituximab (an intravenous medication called a monoclonal antibody), and lenalidomide (an anti-cancer pill).

The purpose of this study is to see if giving the chemotherapy pill lenalidomide after treatment with bendamustine and rituximab is able to prolong the period of time before the cancer starts growing again and causing symptoms.

Detailed description:

Arms:
arm 1: Bendamustine + rituximab induction therapy followed by lenalidomide maintenance therapy

Interventions: intervention 1: Bendamustine intervention 2: Rituximab intervention 3: Lenalidomide
Intervention descriptions: intervention 1: 90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles intervention 2: 375 mg/m2 Day 1 every 28 days for 6 cycles intervention 3: 5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.

Protocol document: